Robert E Molokie

List of Publications by Year
in descending order

114 papers	1,673 citations	361413 20 h-index	345221 36 g-index
115 all docs	115 docs citations	115 times ranked	1841 citing authors

#	Article	IF	Citations
1	Voxelotor and albuminuria in adults with sickle cell anaemia. British Journal of Haematology, 2022, , .	2.5	5
2	Sociodemographic and Clinical Characteristics Associated With Worst Pain Intensity Among Cancer Patients. Pain Management Nursing, 2022, 23, 424-429.	0.9	2
3	HUMAN STUDY COMT and DRD3 haplotype-associated pain intensity and acute care utilization in adult sickle cell disease. Experimental Biology and Medicine, 2022, 247, 1601-1608.	2.4	3
4	Epigenetic regulation of hemoglobin switching in non-human primates. Seminars in Hematology, 2021, 58, 10-14.	3.4	1
5	Acupuncture for chronic pain in adults with sickle cell disease: a mixed-methods pilot study. Acupuncture in Medicine, 2021, 39, 612-618.	1.0	12
6	Effects of reninâ€angiotensin blockade and APOL1 on kidney function in sickle cell disease. EJHaem, 2021, 2, 483-484.	1.0	2
7	Pain, symptom distress, and pain barriers by age among patients with cancer receiving hospice care: Comparison of baseline data. Journal of Geriatric Oncology, 2021, 12, 1068-1075.	1.0	6
8	Antimicrobial resistance is a risk factor for mortality in adults with sickle cell disease. Haematologica, 2021, 106, 1745-1748.	3.5	3
9	Effect of the NAMPT Activator P7C3-A20 on Î³-Globin Expression in Baboon CD34+ Erythroid Cell Cultures. Blood, 2021, 138, 961-961.	1.4	0
10	Biomarker Association with Hypertension in Mild Versus Severe Sickle Cell Disease Genotypes of a Single Center Cohort, in Comparison with African Americans from the Nhanes Study. Blood, 2021, 138, 2051-2051.	1.4	1
11	Defining and Predicting Rapid Egfr Decline in Sickle Cell Disease. Blood, 2021, 138, 122-122.	1.4	1
12	Clinical and Biomarker Predictors for Avascular Necrosis in Sickle Cell Disease. Blood, 2021, 138, 3091-3091.	1.4	0
13	Randomized clinical trial of computerized PAINRelieveItÂ® for patients with sickle cell disease: PAINReportItÂ® and PAINUCopeÂ®. Patient Education and Counseling, 2020, 103, 136-144.	2.2	5
14	Keys to Recruiting and Retaining Seriously Ill African Americans With Sickle Cell Disease in Longitudinal Studies: Respectful Engagement and Persistence. American Journal of Hospice and Palliative Medicine, 2020, 37, 123-128.	1.4	9
15	Sensitivities to Thermal and Mechanical Stimuli: Adults With Sickle Cell Disease Compared to Healthy, Pain-Free African American Controls. Journal of Pain, 2020, 21, 957-967.	1.4	15
16	A QSTâ€based Pain Phenotype in Adults With Sickle Cell Disease: Sensitivity and Specificity of Quality Descriptors. Pain Practice, 2020, 20, 168-178.	1.9	11
17	A Stepped-Wedge Randomized Controlled Trial: Effects of eHealth Interventions for Pain Control Among Adults With Cancer in Hospice. Journal of Pain and Symptom Management, 2020, 59, 626-636.	1.2	17
18	Patients and Caregivers Rate the PAINReportIt Wireless Internet-Enabled Tablet as a Method for Reporting Pain During End-of-Life Cancer Care. Cancer Nursing, 2020, 43, 419-424.	1.5	14

#	Article	IF	Citations
19	Chronic opioid use can be reduced or discontinued after haematopoietic stem cell transplantation for sickle cell disease. British Journal of Haematology, 2020, 191, e70-e72.	2.5	3
20	Early Detection of Acute Chest Syndrome Through Electronic Recording and Analysis of Auscultatory Percussion. IEEE Journal of Translational Engineering in Health and Medicine, 2020, 8, 1-8.	3.7	4
21	Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease. Blood Advances, 2020, 4, 1978-1986.	5.2	28
22	S100B single nucleotide polymorphisms exhibit sex-specific associations with chronic pain in sickle cell disease in a largely African-American cohort. PLoS ONE, 2020, 15, e0232721.	2.5	5
23	Improved health care utilization and costs in transplanted versus non-transplanted adults with sickle cell disease. PLoS ONE, 2020, 15, e0229710.	2.5	14
24	COVIDâ€19 infection in patients with sickle cell disease. British Journal of Haematology, 2020, 189, 851-852.	2.5	90
25	PhenylethanolamineN-methyltransferase gene polymorphisms associate with crisis pain in sickle cell disease patients. Pharmacogenomics, 2020, 21, 269-278.	1.3	5
26	Cathepsin B, a Negative Regulator of Autophagy, Identified As a Novel Therapeutic Drug Target in Sickle Cell Disease. Blood, 2020, 136, 32-32.	1.4	1
27	Cancer Incidence and Chemotherapy Tolerance in Patients with Sickle Cell Disease. Blood, 2020, 136, 24-25.	1.4	0
28	Effects of Hydroxyurea and Renin-Angiotensin Blockade on Kidney Function in Sickle Cell Disease. Blood, 2020, 136, 21-22.	1.4	0
29	Combinatorial Administration of Pharmacological Inhibitors Targeting DNMT1 and KDM1A Produces Synergistic and Additive Increases in F Retiulocytes and Î³-Globin Expression in Normal Baboons. Blood, 2020, 136, 5-5.	1.4	0
30	Effect of Nicotinamide, 1-Methylnicotinamide, and N'-Methylnicotinamide on Erythroid Colony Formation and Î³-Globin Expression in Cultured Baboon CD34+ Cells. Blood, 2020, 136, 4-5.	1.4	0
31	Outcomes in Vaso-Occlusive Crisis Treatment in the Emergency Department Vs. Acute Care Observation Center. Blood, 2020, 136, 22-23.	1.4	1
32	Vaso-Occlusive Events Precipitated By Intraarticular Steroid Injections in Patients with Sickle Cell Disease. Blood, 2020, 136, 2-3.	1.4	0
33	Lower Apache II Score and Exchange Transfusions Predict Better Outcomes in the Intensive Care Unit for Patients with Sickle Cell Disease. Blood, 2020, 136, 18-19.	1.4	0
34	Correction of Point-of-Care International Normalized Ratio (INR) Values in Patients with Sickle Cell Disease. Blood, 2020, 136, 34-35.	1.4	0
35	Complications in Pregnancy of Sickle Cell Disease. Blood, 2020, 136, 32-33.	1.4	0
36	Title is missing!. , 2020, 15, e0229710.		0

#	Article	IF	Citations
37	Title is missing!. , 2020, 15, e0229710.		0
38	Title is missing!. , 2020, 15, e0229710.		0
39	Title is missing!. , 2020, 15, e0229710.		0
40	Kidney ultrasound findings according to kidney function in sickle cell anemia. American Journal of Hematology, 2019, 94, E288-E291.	4.1	4
41	Thermal and mechanical quantitative sensory testing values among healthy African American adults . Journal of Pain Research, 2019, Volume 12, 2511-2527.	2.0	7
42	Vasopressin SNP pain factors and stress in sickle cell disease. PLoS ONE, 2019, 14, e0224886.	2.5	4
43	â€œMaximum tolerated doseâ€•vs â€œfixed lowâ€doseâ€•hydroxyurea for treatment of adults with sickle cell anemia. American Journal of Hematology, 2019, 94, E112-E115.	4.1	7
44	Beta2-Adrenergic Receptor Polymorphisms and Haplotypes Associate With Chronic Pain in Sickle Cell Disease. Frontiers in Pharmacology, 2019, 10, 84.	3.5	10
45	Integration of neuropsychology services in a sickle cell clinic and subsequent healthcare use for pain crises. Clinical Neuropsychologist, 2019, 33, 1195-1211.	2.3	8
46	Use of metformin in patients with sickle cell disease. American Journal of Hematology, 2019, 94, E13-E15.	4.1	5
47	High inpatient dose of opioid at discharge compared to home dose predicts readmission risk in sickle cell disease. American Journal of Hematology, 2019, 94, E5-E7.	4.1	1
48	The AVPR1A Gene and Its Single Nucleotide Polymorphism rs10877969: A Literature Review of Associations with Health Conditions and Pain. Pain Management Nursing, 2018, 19, 430-444.	0.9	4
49	Haploidentical Peripheral Blood Stem Cell Transplantation Demonstrates Stable Engraftment in Adults with Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 1759-1765.	2.0	50
50	Transient receptor potential polymorphism and haplotype associate with crisis pain in sickle cell disease. Pharmacogenomics, 2018, 19, 401-411.	1.3	21
51	Association of Cardiomyopathy With MYBPC3 D389V and MYBPC3^{Î”25bp}Intronic Deletion in South Asian Descendants. JAMA Cardiology, 2018, 3, 481.	6.1	31
52	Differences in Sensory Pain, Expectation, and Satisfaction Reported by Outpatients with Cancer or Sickle Cell Disease. Pain Management Nursing, 2018, 19, 322-332.	0.9	7
53	Performance validity testing in a clinical sample of adults with sickle cell disease. Clinical Neuropsychologist, 2018, 32, 81-97.	2.3	12
54	Opioid doses and acute care utilization outcomes for adults with sickle cell disease: ED versus acute care unit. American Journal of Emergency Medicine, 2018, 36, 88-92.	1.6	18

#	Article	IF	Citations
55	Program expansion of a day hospital dedicated to manage sickle cell pain. American Journal of Hematology, 2018, 93, E20-E21.	4.1	7
56	Erythropoiesisâ€stimulating agents in sickle cell anaemia. British Journal of Haematology, 2018, 182, 602-605.	2.5	9
57	Risk factors for vitamin D deficiency in sickle cell disease. British Journal of Haematology, 2018, 181, 828-835.	2.5	16
58	Genetic variants of GCH1 associate with chronic and acute crisis pain in African Americans with sickle cell disease. Experimental Hematology, 2018, 66, 42-49.	0.4	16
59	Bedside ultrasound as a predictive tool for acute chest syndrome in sickle cell patients. American Journal of Emergency Medicine, 2018, 36, 1855-1861.	1.6	7
60	Glucocorticoid receptor single nucleotide polymorphisms are associated with acute crisis pain in sickle cell disease. Pharmacogenomics, 2018, 19, 1003-1011.	1.3	12
61	Oral administration of the LSD1 inhibitor ORY-3001 increases fetal hemoglobin in sickle cell mice and baboons. Experimental Hematology, 2018, 67, 60-64.e2.	0.4	17
62	The Impact of Selenium Deficiency on a Sickle Cell Disease Mouse Model. Blood, 2018, 132, 3645-3645.	1.4	1
63	Protein Phosphorylation Mechanisms Underlying Chronic Pain in Sickle Cell Disease. Blood, 2018, 132, 3646-3646.	1.4	0
64	Long-Term Stability of the Adult Sickle Cell Quality of Life Measure (ASCQ-Me)â€‹. Blood, 2018, 132, 3576-3576.	1.4	0
65	Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease. Experimental Hematology, 2017, 50, 46-52.	0.4	52
66	Efficacy and safety of long-term RN-1 treatment to increase HbF in baboons. Blood, 2017, 129, 260-263.	1.4	20
67	APOL1 , Î±-thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia. Haematologica, 2017, 102, e1-e6.	3.5	47
68	Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways. Haematologica, 2017, 102, e282-e284.	3.5	4
69	Implementing the PAINRelieveIt Randomized Controlled Trial in Hospice Care: Mechanisms for Success and Meeting PCORI Methodology Standards. Western Journal of Nursing Research, 2017, 39, 924-941.	1.4	4
70	Coping with Pain in the Face of Healthcare Injustice in Patients with Sickle Cell Disease. Journal of Immigrant and Minority Health, 2017, 19, 1449-1456.	1.6	6
71	Management of Sickle Cell Pain Using Pregabalin: A Pilot Study. Pain Management Nursing, 2017, 18, 391-400.	0.9	20
72	Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study. PLoS Medicine, 2017, 14, e1002382.	8.4	107

#	Article	IF	Citations
73	HMOX1 and Acute Kidney Injury in Sickle Cell Anemia. Blood, 2017, 130, 686-686.	1.4	0
74	Conjunctival microvascular hemodynamics following vaso-occlusive crisis in sickle cell disease. Clinical Hemorheology and Microcirculation, 2016, 62, 359-367.	1.7	6
75	Safety and Utility of Quantitative Sensory Testing among Adults with Sickle Cell Disease: Indicators of Neuropathic Pain?. Pain Practice, 2016, 16, 282-293.	1.9	70
76	Toward understanding familyâ€related characteristics of young adults with sickleâ€cell disease or sickleâ€cell trait in the USA. Journal of Clinical Nursing, 2016, 25, 1587-1597.	3.0	6
77	Utility of the revised cardiac risk index for predicting postsurgical morbidity in Hb SC and Hb Sβ+â€thalassemia sickle cell disease. American Journal of Hematology, 2016, 91, E316-7.	4.1	1
78	IL1A rs1800587 associates with chronic noncrisis pain in sickle cell disease. Pharmacogenomics, 2016, 17, 1999-2006.	1.3	9
79	CaMKIIα underlies spontaneous and evoked pain behaviors in Berkeley sickle cell transgenic mice. Pain, 2016, 157, 2798-2806.	4.2	30
80	Patterns of opioid use in sickle cell disease. American Journal of Hematology, 2016, 91, 1102-1106.	4.1	24
81	A randomized controlled pilot study feasibility of a tabletâ€based guided audioâ€visual relaxation intervention for reducing stress and pain in adults with sickle cell disease. Journal of Advanced Nursing, 2016, 72, 1452-1463.	3.3	21
82	Satisfied or not satisfied: pain experiences of patients with sickle cell disease. Journal of Advanced Nursing, 2016, 72, 1398-1408.	3.3	12
83	Perception of young adults with sickle cell disease or sickle cell trait about participation in the <scp>CHOICES</scp> randomized controlled trial. Journal of Advanced Nursing, 2016, 72, 1430-1440.	3.3	12
84	Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve theÂQuality of Life of Adults with Sickle Cell Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 441-448.	2.0	111
85	Reproductive Health CHOICES for Young Adults with Sickle Cell Disease or Trait: Randomized Controlled Trial Outcomes over Two Years. Journal of Genetic Counseling, 2016, 25, 325-336.	1.6	29
86	Phase 1 Evaluation of Oral Tetrahydrouridine-Decitabine As Non-Cytotoxic Epigenetic Disease Modification for Sickle Cell Disease. Blood, 2016, 128, 124-124.	1.4	2
87	Efficacy and Safety of Long-Term Treatment with the LSD1 Inhibitor RN-1 to Increase HbF in Normal, Non-Anemic Baboons. Blood, 2016, 128, 324-324.	1.4	0
88	Platelets decline during <scp>V</scp>asoâ€occlusive crisis as a predictor of acute chest syndrome in sickle cell disease. American Journal of Hematology, 2015, 90, E228-9.	4.1	12
89	Composite Pain Index: Reliability, Validity, and Sensitivity of a Patient-Reported Outcome for Research. Pain Medicine, 2015, 16, 1341-1348.	1.9	23
90	Conjunctival and pulmonary hemodynamic properties in sickle cell disease subjects with and without pulmonary hypertension. Clinical Case Reports (discontinued), 2015, 3, 1038-1041.	0.5	4

#	Article	IF	Citations
91	Prevalence of pain-related single nucleotide polymorphisms in patients of African origin with sickle cell disease. Pharmacogenomics, 2015, 16, 1795-1806.	1.3	15
92	Perceived Injustice Predicts Stress and Pain in Adults with Sickle Cell Disease. Pain Management Nursing, 2015, 16, 294-306.	0.9	31
93	Chronic Opioid Use Pattern in Adult Patients with Sickle Cell Disease. Blood, 2015, 126, 3400-3400.	1.4	3
94	Utility of the Revised Cardiac Index Score for Predicting Post-Surgical Outcome in Hb SC or SBeta+ -Thalassemia Sickle Cell Disease. Blood, 2015, 126, 3413-3413.	1.4	0
95	Impact of a Dedicated Sickle Cell Acute Care Observation Unit on Rate of Hospital Admission for Acute Pain Crisis. Blood, 2015, 126, 4584-4584.	1.4	0
96	Evaluation of the SCKnowIQ Tool and Reproductive CHOICES Intervention Among Young Adults With Sickle Cell Disease or Sickle Cell Trait. Clinical Nursing Research, 2014, 23, 421-441.	1.6	25
97	Does cold hypersensitivity increase with age in sickle cell disease?. Pain, 2014, 155, 2439-2440.	4.2	5
98	Mechanism-driven phase I translational study of trifluoperazine in adults with sickle cell disease. European Journal of Pharmacology, 2014, 723, 419-424.	3.5	38
99	Outpatient Pain Predicts Subsequent One-Year Acute Health Care Utilization Among Adults With Sickle Cell Disease. Journal of Pain and Symptom Management, 2014, 48, 65-74.	1.2	37
100	Dopamine D3 Receptor Ser9Gly and Catechol-O-Methyltransferase Val158Met Polymorphisms and Acute Pain in Sickle Cell Disease. Anesthesia and Analgesia, 2014, 119, 1201-1207.	2.2	33
101	The Tet Dioxygenase Co-Factor Ascorbic Acid Reduces DNA Methylation and Increases Expression of the Î³-Globin Gene and Acts in a Combinatorial Manner with HbF-Inducing Drugs Targeting Repressive Epigenetic Modifications. Blood, 2014, 124, 334-334.	1.4	4
102	Hemoglobinuria Is a Risk Factor For Kidney Disease Progression In Sickle Cell Anemia. Blood, 2013, 122, 996-996.	1.4	0
103	Clinical Efficacy and Safety of Erythroid Stimulating Agents in Sickle Cell Disease. Blood, 2012, 120, 3218-3218.	1.4	1
104	A Case Series: Chiari Malformation and Sickle Cell Disease. Blood, 2012, 120, 4772-4772.	1.4	25
105	Clinical and Laboratory Predictors for Renal Damage in Sickle Cell Disease. Blood, 2012, 120, 3252-3252.	1.4	0
106	Cognitive Testing of PAINReportIt in Adult African Americans With Sickle Cell Disease. CIN - Computers Informatics Nursing, 2010, 28, 141-150.	0.5	43
107	Pain Barriers. Nursing Research, 2010, 59, 93-101.	1.7	22
108	Neurobiological Mechanisms of Pain in Sickle Cell Disease. Hematology American Society of Hematology Education Program, 2010, 2010, 403-408.	2.5	58

#	Article	IF	Citations
109	Patient-Reported Outcomes: Descriptors of Nociceptive and Neuropathic Pain and Barriers to Effective Pain Management in Adult Outpatients With Sickle Cell Disease. Journal of the National Medical Association, 2010, 102, 18-27.	0.8	152
110	Initial Experience with the IMPROVE Trial-a Phase III Analgesic Trial for Hospitalized Sickle Cell Painful Episodes. Blood, 2010, 116, 2667-2667.	1.4	1
111	A Comparison of Two Pain Assessment Tools, the Adolescent Pediatric Pain Tool and PAINReportIt and Use of the Composite Pain Index in Sickle Cell Disease. Blood, 2010, 116, 2648-2648.	1.4	0
112	Fever In Hospitalized Adult Patients with Sickle Cell Disease. Blood, 2010, 116, 2652-2652.	1.4	0
113	Response to Therapy with Imatinib Mesylate in Patients with CML Is Poor in Non-Caucasian Patients.. Blood, 2004, 104, 2937-2937.	1.4	0
114	Tetrahydrouridine, cytidine analogues, and hemoglobin F. American Journal of Hematology, 1985, 18, 283-288.	4.1	16